Concurrent Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Concurrent Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.23M	Sell	9,484 -250	-3%	-$117K	0.05%	393
2025 Q4	$4.41M	Buy	9,734 +6,895	+243%	+$2.97M	0.05%	361
2025 Q3	$1.11M	Sell	2,839 -281	-9%	-$117K	0.02%	623
2025 Q2	$1.39M	Sell	3,120 -93	-3%	-$42.9K	0.03%	517
2025 Q1	$1.56M	Buy	3,213 +1,141	+55%	+$532K	0.04%	421
2024 Q4	$834K	Hold	2,072	–	–	0.02%	532
2024 Q3	$964K	Buy	2,072 +541	+35%	+$260K	0.03%	471
2024 Q2	$718K	Buy	1,531 +244	+19%	+$106K	0.02%	507
2024 Q1	$538K	Buy	1,287 +621	+93%	+$263K	0.02%	531
2023 Q4	$271K	Buy	+666	New	+$246K	0.01%	680

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Concurrent Investment Advisors's VRTX Position: Q1 2026 in Review

Concurrent Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q1 2026, selling an estimated $117K and leaving 9,484 shares worth $4.23M. The position accounts for 0.05% of the portfolio, ranked #393.

Concurrent Investment Advisors first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $4.41M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Concurrent Investment Advisors held 9,484 shares of Vertex Pharmaceuticals worth $4.23M as of Q1 2026.
Concurrent Investment Advisors sold 250 Vertex Pharmaceuticals shares in Q1 2026, an estimated $117K.
Vertex Pharmaceuticals made up 0.05% of Concurrent Investment Advisors's portfolio in Q1 2026, its #393 holding.
Concurrent Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Concurrent Investment Advisors's Vertex Pharmaceuticals position peaked at $4.41M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.